Spero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) will present a corporate update at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:00 a.m. ET. The presentation will be led by Ankit Mahadevia, M.D., President and CEO. Interested individuals can access the webcast on Spero's website under the 'Events and Presentations' section. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, including its lead product candidate, tebipenem HBr, aimed at treating MDR Gram-negative infections.

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the Jefferies 2020 Virtual Healthcare Conference at 9:00 a.m. ET on Thursday, June 4, 2020.

A webcast of the presentation may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab.  A replay of the presentation will be archived on the website for 90 days following the conclusion of the event.

About Spero
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.

Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan disease caused by pulmonary non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Spero Investor and Media Contact:
Sharon Klahre
Senior Director, Investor Relations
857-242-1547
IR@sperotherapeutics.com

 

FAQ

What is the date and time of Spero Therapeutics' presentation at the Jefferies 2020 Virtual Healthcare Conference?

Spero Therapeutics' presentation is scheduled for June 4, 2020, at 9:00 a.m. ET.

Who will present at the Jefferies 2020 Virtual Healthcare Conference on behalf of Spero Therapeutics?

Ankit Mahadevia, M.D., President and CEO of Spero Therapeutics, will provide the corporate update.

How can I access the Spero Therapeutics presentation webcast?

The webcast can be accessed through Spero Therapeutics' website under the 'Events and Presentations' page in the 'Investors and Media' section.

What is Spero Therapeutics' focus in the biopharmaceutical space?

Spero Therapeutics focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What is Spero Therapeutics' lead product candidate?

Spero's lead product candidate is tebipenem HBr, an oral carbapenem-class antibiotic for treating MDR Gram-negative infections.